BR112014005398A2 - peptídeo que inibe a atividade de metaloproteinases de matriz e uso do mesmo - Google Patents
peptídeo que inibe a atividade de metaloproteinases de matriz e uso do mesmoInfo
- Publication number
- BR112014005398A2 BR112014005398A2 BR112014005398A BR112014005398A BR112014005398A2 BR 112014005398 A2 BR112014005398 A2 BR 112014005398A2 BR 112014005398 A BR112014005398 A BR 112014005398A BR 112014005398 A BR112014005398 A BR 112014005398A BR 112014005398 A2 BR112014005398 A2 BR 112014005398A2
- Authority
- BR
- Brazil
- Prior art keywords
- peptide
- activity
- inhibiting
- matrix
- inhibits
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/06—Preparations for care of the skin for countering cellulitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Birds (AREA)
- Biochemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
Abstract
abstract the present invention relates to a peptide inhibiting a matrix metalloproteanases activity and use thereof. the peptide inhibiting a matrix metalloproteanases activity exhibits an excellent efficacy of improving the condition of skin by directly inhibiting the matrix metalloproteanases activity. in addition, a composition containing the peptide of the invention has excellent bioactivities of inhibiting the activity of hyaluronic acid degrading enzymes, adipogenesis in fat cells, angiogenesis, and the like, thereby being useful for the treatment of various disease such as anti-obesity, anti-cancer, anti-inflammation, and the like, and skin permeability is excellent due to the small size of the peptide, thereby being useful in various fields. the peptide of the invention having excellent activity and safety can be advantageously applied to drugs, quasi-drugs, and cosmetics. tradução do resumo resumo patente de invenção: "peptídeo que inibe a atividade de metaloproteinases de matriz e uso do mesmo". a presente invenção refere-se a um peptídeo que inibe a atividade de metaloproteinases de matriz e uso do mesmo. o peptídeo que inibe a atividade de metaloproteinases de matriz exibe excelente eficácia em melhorar a condição da pele inibindo diretamente a atividade das metaloproteinases de matriz. em adição, uma composição contendo o peptídeo da invenção tem excelentes bioatividades de inibir a atividade de enzimas que degradam o ácido hialurônico, a adipogênese em células de gordura, angiogênese, e similares, sendo assim útil para o tratamento de várias doenças tais como obesidade, câncer, inflamação, e similares, e para a permeabilidade da pele é excelente devido ao pequeno tamanho do peptídeo, sendo assim útil em vários campos. o peptídeo da invenção com excelente atividade e segurança pode ser vantajosamente aplicado a fármacos, pseudofármacos, e cosméticos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020110091923A KR101363455B1 (ko) | 2011-09-09 | 2011-09-09 | 매트릭스 메탈로프로테아제 활성 억제 펩타이드 및 이의 용도 |
KR10-2011-0091923 | 2011-09-09 | ||
PCT/KR2011/008272 WO2013035931A1 (ko) | 2011-09-09 | 2011-11-02 | 매트릭스 메탈로프로테아제 활성 억제 펩타이드 및 이의 용도 |
Publications (2)
Publication Number | Publication Date |
---|---|
BR112014005398A2 true BR112014005398A2 (pt) | 2017-04-04 |
BR112014005398B1 BR112014005398B1 (pt) | 2021-08-31 |
Family
ID=47832351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014005398-7A BR112014005398B1 (pt) | 2011-09-09 | 2011-11-02 | Agente de preenchimento cutâneo que inibe a atividade de metaloproteinases de matriz |
Country Status (8)
Country | Link |
---|---|
US (1) | US9303064B2 (pt) |
EP (1) | EP2754665B1 (pt) |
JP (1) | JP5908589B2 (pt) |
KR (1) | KR101363455B1 (pt) |
CN (1) | CN104024271B (pt) |
BR (1) | BR112014005398B1 (pt) |
ES (1) | ES2637290T3 (pt) |
WO (1) | WO2013035931A1 (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101744959B1 (ko) * | 2014-12-05 | 2017-06-12 | (주)케어젠 | 피부상태 개선 활성을 갖는 펩타이드 및 이의 용도 |
KR101669140B1 (ko) * | 2015-04-28 | 2016-10-26 | (주)케어젠 | 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도 |
KR101943081B1 (ko) * | 2017-08-31 | 2019-01-29 | (주)케어젠 | 주름 개선 활성을 나타내는 펩타이드 및 이의 용도 |
KR102011979B1 (ko) * | 2017-10-16 | 2019-08-19 | (주)케어젠 | 세사몰과 펩타이드의 결합체를 유효성분으로 함유하는 숙취 해소용 조성물 |
KR102111025B1 (ko) * | 2018-06-05 | 2020-05-15 | 고려대학교 산학협력단 | 신경줄기세포 배양액을 유효성분으로 함유하는 항노화 또는 주름억제용 화장료 조성물 및 이의 제조 방법 |
JP6709440B2 (ja) * | 2018-06-08 | 2020-06-17 | 学校法人福岡大学 | 肥厚性瘢痕の形成抑制用組成物 |
TW202132327A (zh) * | 2019-11-08 | 2021-09-01 | 日商大正製藥股份有限公司 | 具有mmp2阻礙作用之多肽 |
US20230220006A1 (en) * | 2020-06-08 | 2023-07-13 | Ninebiopharm Co., Ltd. | Regentide-034 and composition for improving condition of skin, containing same |
CN115701979A (zh) * | 2020-06-08 | 2023-02-14 | 九生药业股份有限公司 | 包含regentide-034及regentide-041的皮肤保护或皱纹改善用组合物 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE219776T1 (de) * | 1989-03-21 | 2002-07-15 | Us Secretary United States Dep | Matrizenmetalloproteinase-inhibitor-peptide |
EP0404750B1 (en) * | 1989-05-26 | 1994-08-10 | Washington University | Tissue inhibitor of metalloproteases (TIMP-2) |
SE9403526D0 (sv) | 1994-10-14 | 1994-10-14 | Astra Ab | New Peptides |
FI980604A0 (fi) | 1998-03-18 | 1998-03-18 | Univ Helsinki Licensing | Nya matrismetalloproteinasinhibitorer och -regulatorer |
CA2367213A1 (en) * | 1999-03-18 | 2000-09-21 | Children's Medical Center Corporation | Novel antiangiogenic peptides |
JP4342027B2 (ja) * | 1999-04-01 | 2009-10-14 | オリエンタル酵母工業株式会社 | Timp修飾体 |
US7041787B2 (en) * | 2000-12-29 | 2006-05-09 | Kimberly-Clark Worldwide, Inc. | Design and use of advanced zinc chelating peptides to regulate matrix metalloproteinases |
US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
US7183256B2 (en) * | 2003-03-21 | 2007-02-27 | Cleveland Clinic Foundation | TIMP3 as VEGF inhibitor |
WO2004096832A2 (en) * | 2003-04-29 | 2004-11-11 | Children's Medical Center Corporation | Novel antiangiogenic peptides |
FI20040572A0 (fi) | 2004-04-23 | 2004-04-23 | Ctt Cancer Targeting Tech Oy | Matriisi-metalloproteinaasin aktiviteetin inhibiittorit |
JP2006117592A (ja) * | 2004-10-22 | 2006-05-11 | Maruzen Pharmaceut Co Ltd | マトリックスメタロプロテアーゼ−2阻害剤 |
KR100831335B1 (ko) * | 2006-06-22 | 2008-05-22 | 부경대학교 산학협력단 | 인간 피부 섬유아세포에서 메트릭스메탈로프로테이나제-2의 발현 및 활성을 억제시키는키토올리고사카라이드 화합물 및 이를 함유한 메트릭스메탈로프로테이나제-2 억제제 |
JP2009051790A (ja) * | 2007-08-29 | 2009-03-12 | Maruzen Pharmaceut Co Ltd | 抗酸化剤、抗老化剤、抗炎症剤、育毛剤、抗肥満剤、及び美白剤、並びに化粧料及び美容用飲食品 |
ES2330291B1 (es) * | 2008-02-29 | 2010-10-18 | Lipotec Sa | Peptidos utiles en el tratamiento de la piel, mucosas y/o cuero cabelludo y su uso en composiciones cosmeticas o farmaceuticas. |
-
2011
- 2011-09-09 KR KR1020110091923A patent/KR101363455B1/ko active IP Right Grant
- 2011-11-02 CN CN201180074350.7A patent/CN104024271B/zh active Active
- 2011-11-02 EP EP11871853.5A patent/EP2754665B1/en active Active
- 2011-11-02 WO PCT/KR2011/008272 patent/WO2013035931A1/ko active Application Filing
- 2011-11-02 JP JP2014529600A patent/JP5908589B2/ja active Active
- 2011-11-02 ES ES11871853.5T patent/ES2637290T3/es active Active
- 2011-11-02 US US14/343,850 patent/US9303064B2/en active Active
- 2011-11-02 BR BR112014005398-7A patent/BR112014005398B1/pt active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
US9303064B2 (en) | 2016-04-05 |
EP2754665A1 (en) | 2014-07-16 |
KR20130028403A (ko) | 2013-03-19 |
CN104024271A (zh) | 2014-09-03 |
ES2637290T3 (es) | 2017-10-11 |
KR101363455B1 (ko) | 2014-02-21 |
EP2754665A4 (en) | 2015-04-01 |
US20140328782A1 (en) | 2014-11-06 |
JP2014526459A (ja) | 2014-10-06 |
EP2754665B1 (en) | 2017-05-17 |
JP5908589B2 (ja) | 2016-05-11 |
WO2013035931A1 (ko) | 2013-03-14 |
BR112014005398B1 (pt) | 2021-08-31 |
CN104024271B (zh) | 2016-06-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014005398A2 (pt) | peptídeo que inibe a atividade de metaloproteinases de matriz e uso do mesmo | |
BRPI0925036B8 (pt) | uso de trans-t-butil ciclo-hexanol, composição cosmética, medicamento, seus usos e processos para tratar irritação na pele | |
BR112015003125B8 (pt) | ingrediente hidratante cosmético, uso de uma combinação e de uma composição de cosmético, mistura de ingredientes cosméticos, composição cosmética destinada à administração tópica, e, composição de limpeza | |
BR112012024379A2 (pt) | "peptídeos glucagon, seu uso, bem como composição farmacêutica" | |
CR20120596A (es) | 5-fluoro-1h-pirazolopiridinas sustituidas y su uso | |
BR112015011158A8 (pt) | triazolopirazina, seu uso e preparação farmacêutica | |
GB201021937D0 (en) | Skin sanitizer compositions comprising alcohol based emulsion | |
MY167691A (en) | A pharmaceutical spray composition comprising a vitamin d analogue and a corticosteroid | |
BR112014010275A2 (pt) | formulações para tratamento de diabetes | |
BR112015016796A8 (pt) | modulador de receptor de androgênio, composição farmacêutica que os compreende e usos do mesmo | |
BR112012006891A2 (pt) | formulação de hydrogel compreendendo uma solução aquosa com potencial oxidativo redutivo | |
CR11724A (es) | Agente para tratar enfermedades | |
AR084932A1 (es) | Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica | |
BR112014018421A8 (pt) | Composições antimicrobianas compreendendo dgla, 15-ohepa e/ou 15-hetre e métodos de uso das mesmas | |
BR112012009432A2 (pt) | anticorpo anti-hsv | |
MX366773B (es) | Composicion topica para lavado para su uso en pacientes con acne. | |
BR112012005044A2 (pt) | composições que compreendem tramadol e celecoxib no tratamento de dor. | |
BR112014031788A2 (pt) | composições e métodos para o tratamento de diabetes | |
MX2010004613A (es) | Composicion topica. | |
BR112013026698A2 (pt) | formulações do tipo tópica compreendendo depsipeptídeo cíclico | |
BR112013010325A2 (pt) | composições para o tratamento de úlceras periféricas de várias origens | |
CO6660486A2 (es) | Composición tópica famacéutica o cosmética útil para el tratamiento de enfermedades o condiciones que cursan con un déficit de la maduración de la envoltura córnea | |
BR112012024887A2 (pt) | grânulos de quitosana, preenchedor, processo para preparar os grânulos de quitosana, kit e disposto de injeção | |
BR112015010223A2 (pt) | compostos tricíclicos para o uso no tratamento e/ou controle de obesidade | |
BR112015014261A8 (pt) | composto de danazol, seu uso e formulação farmacêutica compreendendo este |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/11/2011, OBSERVADAS AS CONDICOES LEGAIS. |